Search Result

Results for "

bile acid metabolism

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apical Sodium-Dependent Bile Acid Transporter (1) G protein-coupled Bile Acid Receptor 1 (10) Mitochondrial Metabolism (2) Acetyl-CoA Carboxylase (2) Akt (2) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (4) Apoptosis (4) Autophagy (9) Bacterial (4) Biochemical Assay Reagents (2) Constitutive Androstane Receptor (1) Cytochrome P450 (1) DNA/RNA Synthesis (4) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (4) Endogenous Metabolite (31) FOXO (2) FXR (23) GLP Receptor (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Interleukin Related (1) Isotope-Labeled Compounds (7) LDLR (2) Liposome (1) Microtubule/Tubulin (2) mRNA (1) NF-κB (4) p38 MAPK (2) PI3K (2) Pregnane X Receptor (PXR) (1) Reactive Oxygen Species (ROS) (4) Reference Standards (12) ROCK (2) Sirtuin (1) TNF Receptor (3)
By Research Areas:	Cancer (17) Cardiovascular Disease (4) Endocrinology (3) Infection (7) Inflammation/Immunology (8) Metabolic Disease (41) Neurological Disease (6)
Oligonucleotides:	Emulsifiers (1) mRNA (1) Cholesterol (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Mitochondrial Metabolism Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N0593

Deoxycholic acid Maximum Cited Publications 27 Publications Verification Cholanoic acid; Desoxycholic acid	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-76847

Chenodeoxycholic Acid 20+ Cited Publications CDCA	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593A

Deoxycholic acid sodium salt 25+ Cited Publications Sodium deoxycholate	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-B0172B

Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid	Endogenous Metabolite	Endocrinology
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .

HY-76847S

Chenodeoxycholic Acid-d4 1 Publications Verification CDCA-d₄	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	FXR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-B1907

Rifamycin sodium 2 Publications Verification Rifamycin SV sodium	Antibiotic Bacterial DNA/RNA Synthesis	Infection Inflammation/Immunology
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-N0010

Geniposidic acid 5+ Cited Publications	FXR Sirtuin TNF Receptor Interleukin Related	Metabolic Disease
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Cancer
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-W587530

6-Oxolithocholic acid 6-Ketolithocholic acid	Endogenous Metabolite Apoptosis	Endocrinology
6-Oxolithocholic acid is a bile acid metabolite derived from Lithocholic acid (HY-B0172). 6-Oxolithocholic acid has high cytotoxicity and can induce apoptosis, especially in hepatocytes. 6-Oxolithocholic acid can participate in the regulation of bile acid metabolism and synthesis and affect the metabolic pathway of cholesterol. 6-Oxolithocholic acid can be used to study the role of bile acids in health and disease, especially in the context of digestive and liver diseases .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0468

Rebaudioside D 1 Publications Verification	FXR Acetyl-CoA Carboxylase	Metabolic Disease
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-41325

7,12-Diketolithocholic acid 7,12-Dioxolithocholic acid; 3-Hydroxy-7,12-diketocholanoic acid; 7,12-Diketo-LCA	Endogenous Metabolite	Others
7,12-Diketolithocholic acid (7,12-Diketo-LCA) is a bile acid, which can be produced in the host-gut microbial co-metabolism of the bile acid pool .

HY-133890

Tauro-α-muricholic acid 2 Publications Verification T-α-MCA	Endogenous Metabolite FXR	Neurological Disease Metabolic Disease
Tauro-α-muricholic acid (T-α-MCA) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-106539

Colesevelam hydrochloride	FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor	Metabolic Disease Cancer
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

HY-113478S

Ursodeoxycholic acid-d4 Ursodeoxycholate-d₄; Ursodiol-d₄; UDCA-d₄	Isotope-Labeled Compounds	Infection Metabolic Disease
Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol	Liposome	Others
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-76847A

Chenodeoxycholic acid sodium 20+ Cited Publications CDCA sodium	FXR Autophagy Endogenous Metabolite	Metabolic Disease Cancer
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847R

Chenodeoxycholic Acid (Standard) 20+ Cited Publications CDCA (Standard)	Reference Standards FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N2853

D-α-Tocopherylquinone α-Tocopherylquinone	Reactive Oxygen Species (ROS)	Others
D-α-Tocopherylquinone (α-Tocopherylquinone) is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is an oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant. D-α-Tocopherylquinone reduces cellular oxidative damage produced by oxidized lipids. D-α-Tocopherylquinone binds to a liver cytosolic protein with a molecular mass of about 40 kDa. D-α-Tocopherylquinone binds to glurathione-S-transferase (GST) and can be transported to the site of metabolism or excreted in the bile .

HY-N0430

Coptisine Coptisin	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N11257

6,7-Diketolithocholic acid 6,7-DiketoLCA	Others
6,7-Diketolithocholic acid (6,7-DiketoLCA) is an important bioactive compound with anti-inflammatory and bile acid metabolism regulating activities. 6,7-Diketolithocholic acid can affect lipid metabolism and regulate the balance of glucose and lipid metabolism in the body. 6,7-Diketolithocholic acid has also been studied for the inhibition of diseases related to abnormal cholesterol metabolism.

HY-B1907A

Rifamycin 2 Publications Verification Rifamycin SV	Antibiotic Bacterial DNA/RNA Synthesis	Infection
Rifamycin (Rifamycin SV) is an orally active ansamycin antibiotic. Rifamycin inhibits DNA-dependent RNA synthesis. Rifamycin has antibacterial activity against Mycobacterium tuberculosis. Rifamycin interferes with hepatic bile acid metabolism. Rifamycin has anti-inflammatory effects. Rifamycin can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Infection Metabolic Disease Cancer
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Endogenous Metabolite FXR	Neurological Disease Metabolic Disease
Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-N0593R

Deoxycholic acid (Standard) 20+ Cited Publications Cholanoic acid(Standard); Desoxycholic acid (Standard)	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite	Metabolic Disease
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593AR

Deoxycholic acid sodium salt (Standard) Sodium deoxycholate (Standard)	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Reference Standards	Metabolic Disease
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N15317

Phocaecholic acid β-Phocaecholic acid	Drug Metabolite	Metabolic Disease
Phocaecholic acid (β-Phocaecholic acid) is a bile acid found in duck bile. Phocaecholic acid can be excreted into bile and partially decarboxylated to nor-chenodeoxycholic acid in rats. Phocaecholic acid is promising for research of bile acid metabolism and related diseases .

HY-W278566

Saluamine	Drug Metabolite	Cardiovascular Disease Metabolic Disease
Saluamine is an important N-dealkylated metabolite of Furosemide (HY-B0135) that is produced by microbial transformation and bile metabolism. Saluamine is a contaminant .

HY-76847S3

Chenodeoxycholic acid-d5 CDCA-d₅	Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C CDCA-¹³C	FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-W587978

12β-Hydroxyisocholic acid Lagocholic acid; 3α,7α,12β-Trihydroxy-5β-cholanic acid	Endogenous Metabolite Drug Isomer	Metabolic Disease
12β-Hydroxyisocholic acid (Lagocholic acid) is a bile acid isomer that can be used in the study of bile acid metabolism .

HY-E70245

Cholyl-CoA Cholyl-coenzyme A	Biochemical Assay Reagents	Metabolic Disease
Cholyl-CoA (Cholyl-coenzyme A) is a biologically active steroidal acyl-coenzyme A intermediate. Cholyl-CoA reacts with taurine in the presence of liver supernatant enzymes to promote the synthesis of taurocholic acid. Cholyl-CoA is formed by the activation of cholic acid with coenzyme A. Cholyl-CoA plays a key role in the biosynthesis, metabolism and conjugation reactions of bile acids .

HY-W740611

Trihydroxycoprostane	Drug Intermediate	Inflammation/Immunology
Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders .

HY-129982

SC-435	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
SC-435 is an orally effective *apical sodium codependent bile* acid transporter (ASBT)** inhibitor. SC-435 effectively removes neurotoxic bile acids and ammonia from the blood by inhibiting intestinal ASBT, thereby alleviating liver and brain damage caused by liver failure. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-P2879B

Cholesterol esterase, Candida cylindracea	Endogenous Metabolite Biochemical Assay Reagents	Metabolic Disease
Cholesterol esterase, Candida cylindracea is an enzyme located in the intestines that hydrolyzes cholesterol esters into cholesterol and free fatty acids. Also known as bile salt-stimulated lipase or carboxylester lipase, this enzyme facilitates cholesterol metabolism and absorption in the body. It can also be used as a biochemical reagent, and is employed in conjunction with cholesterol oxidase (HY-P2848) to measure cholesterol levels .

HY-N3021R

D-chiro-Inositol (Standard)	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-179875

N-Cholyl-L-leucine	Endogenous Metabolite	Metabolic Disease
N-Cholyl-L-leucine is a bile acid-amino acid conjugate, mainly produced by intestinal microorganisms. N-Cholyl-L-leucine can be used as a biomarker for premature infants and is also employed in the study of bile acid metabolism .

HY-76847S1

Chenodeoxycholic Acid-d9 CDCA-d₉	Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy	Metabolic Disease Cancer
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0468R

Rebaudioside D (Standard)	Reference Standards Acetyl-CoA Carboxylase FXR	Metabolic Disease
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-13771S1

Ursodeoxycholic acid-13C Ursodeoxycholate-¹³C; Ursodiol-¹³C; UDCA-¹³C	Isotope-Labeled Compounds G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite	Cancer
Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-W587451

Cholic acid 3-O-glucuronide disodium OCA-3-glucuronide disodium	FXR	Metabolic Disease
Cholic acid 3-O-glucuronide (OCA-3-glucuronide) disodium is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 91.5 μM. Cholic acid 3-O-glucuronide is promising for research of bile acid metabolism and detoxification .

HY-173033

MI-883	Pregnane X Receptor (PXR) Constitutive Androstane Receptor Cytochrome P450	Metabolic Disease
MI-883 is the orally active agonist for Constitutive Androstane Receptor (CAR, EC₅₀=73 nM) and the antagonist for Pregnane X Receptor (PXR, IC₅₀=0.1 μM). MI-883 stimulates CAR LBD assembly (EC₅₀=0.38 µM) and CAR3 variant activation (EC₅₀=0.074 µM), induces CYP2B6 mRNA expression in HepaRG and primary human hepatocytes. MI-883 inhibits basal PXR activity IC₅₀=2.03 µM) in transiently transfected HepG2 cells, blocks CYP3A4 mRNA expression in HepG2. MI-883 regulates cholesterol metabolism and bile acid excretion, improves hypercholesterolemia in mouse models .

HY-B0172BR

Isolithocholic acid (Standard) 3β-Hydroxy-5β-cholanic acid (Standard); 3-Epilithocholic acid (Standard); β-Lithocholic acid (Standard)	Reference Standards Endogenous Metabolite	Endocrinology
Isolithocholic acid (Standard) is the analytical standard of Isolithocholic acid. This product is intended for research and analytical applications. Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate[1][2].

HY-N0593B

Deoxycholic acid sodium hydrate Cholanoic acid sodium hydrate; Desoxycholic acid sodium hydrate	Endogenous Metabolite G protein-coupled Bile Acid Receptor 1	Metabolic Disease
Deoxycholic acid (cholanoic acid) sodium hydrate, a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-101108R

Tazarotenic acid (Standard) AGN 190299 (Standard)	Reference Standards Drug Metabolite	Others
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-121110

Fexarene	FXR	Metabolic Disease
Fexarene is a potent and selective nonsteroidal Farnesoid X Receptor (FXR) agonist with an EC₅₀ of 36 nM. Fexarene can be used in studies of cholesterol and bile acid metabolism .

HY-135221R

Cefcapene pivoxil hydrochloride (Standard)	Reference Standards Bacterial Antibiotic	Infection
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

Cat. No.	Product Name

HY-L208

Bile Acids Library

61 compounds

Bile acids are a class of amphiphilic molecules derived from the metabolic breakdown of cholesterol, primarily synthesized in the liver, and play a crucial role in the intestines. Based on their structural characteristics, bile acids are mainly divided into two categories: free bile acids (including Cholic acid, Deoxycholic acid, Chenodeoxycholic acid) and conjugated bile acids (including Glycocholic acid, Glycochenodeoxycholic acid, Taurocholic acid, etc.). Bile acids play a significant role in the pathophysiological research of liver and gastrointestinal diseases and are closely associated with the occurrence of metabolic diseases such as obesity, type II diabetes, non-alcoholic fatty liver disease, and atherosclerosis. Bile acids maintain metabolic balance within the body by regulating sugar metabolism, lipid metabolism, and amino acid metabolism, and they influence the activity of metabolism-related enzymes and transporters. In addition, Bile acids can also be used to construct a bile acid metabolism research platform, which helps to delve into the metabolic pathways and dynamic changes of bile acids in living organisms and aids in identifying new biomarkers for certain diseases.

MCE included 61 bile acids, including Cholic acid, Deoxycholic acid, Glycocholic acid, etc., which are effective tools for the study of liver and gallbladder diseases.

Cat. No.	Product Name	Type

HY-133971

Cholesterol 5α,6α-epoxide

5α,6α-Epoxycholesterol

Biochemical Assay Reagents

Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13771

Ursodeoxycholic acid 25+ Cited Publications Ursodeoxycholate; Ursodiol; UDCA	Human Gut Microbiota Metabolites Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-N0593

Deoxycholic acid Maximum Cited Publications 27 Publications Verification Cholanoic acid; Desoxycholic acid	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-76847

Chenodeoxycholic Acid 20+ Cited Publications CDCA	Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N0593A

Deoxycholic acid sodium salt 25+ Cited Publications Sodium deoxycholate	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-B0172B

Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .

HY-N9933

Tauro-β-muricholic acid 4 Publications Verification TβMCA	Structural Classification Human Gut Microbiota Metabolites Animals Endogenous metabolite Steroids Source Classification	FXR Apoptosis
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC₅₀=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis .

HY-B1907

Rifamycin sodium 2 Publications Verification Rifamycin SV sodium	Infection Microorganisms Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	Antibiotic Bacterial DNA/RNA Synthesis
Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-N0010

Geniposidic acid 5+ Cited Publications	Structural Classification other families Iridoids Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FXR Sirtuin TNF Receptor Interleukin Related
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-13771A

Ursodeoxycholic acid sodium 25+ Cited Publications Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium	Microorganisms Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 FXR Endogenous Metabolite
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0468

Rebaudioside D 1 Publications Verification	Structural Classification other families Classification of Application Fields Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Source Classification Food Research	FXR Acetyl-CoA Carboxylase
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-133890

Tauro-α-muricholic acid 2 Publications Verification T-α-MCA	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite FXR
Tauro-α-muricholic acid (T-α-MCA) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-76847A

Chenodeoxycholic acid sodium 20+ Cited Publications CDCA sodium	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	FXR Autophagy Endogenous Metabolite
Chenodeoxycholic acid sodium is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847R

Chenodeoxycholic Acid (Standard) 20+ Cited Publications CDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Reference Standards FXR Endogenous Metabolite Autophagy
Chenodeoxycholic Acid (Standard) is the analytical standard of Chenodeoxycholic Acid. This product is intended for research and analytical applications. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-N2853

D-α-Tocopherylquinone α-Tocopherylquinone	Quinones Microorganisms Classification of Application Fields Benzene Quinones Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS)
D-α-Tocopherylquinone (α-Tocopherylquinone) is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is an oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant. D-α-Tocopherylquinone reduces cellular oxidative damage produced by oxidized lipids. D-α-Tocopherylquinone binds to a liver cytosolic protein with a molecular mass of about 40 kDa. D-α-Tocopherylquinone binds to glurathione-S-transferase (GST) and can be transported to the site of metabolism or excreted in the bile .

HY-N0430

Coptisine Coptisin	Alkaloids Structural Classification Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Alkaloids Structural Classification Chelidonium majus Classification of Application Fields Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Papaveraceae Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N11257

6,7-Diketolithocholic acid 6,7-DiketoLCA	Animals Terpenoids Diterpenoids Source Classification	Others
6,7-Diketolithocholic acid (6,7-DiketoLCA) is an important bioactive compound with anti-inflammatory and bile acid metabolism regulating activities. 6,7-Diketolithocholic acid can affect lipid metabolism and regulate the balance of glucose and lipid metabolism in the body. 6,7-Diketolithocholic acid has also been studied for the inhibition of diseases related to abnormal cholesterol metabolism.

HY-13771R

Ursodeoxycholic acid (Standard) Ursodeoxycholate (Standard); Ursodiol (Standard); UDCA (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Other disease Disease markers Endogenous metabolite Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 FXR Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .

HY-133890A

Tauro-α-muricholic acid sodium 2 Publications Verification T-α-MCA sodium	Structural Classification Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite FXR
Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-N0593R

Deoxycholic acid (Standard) 20+ Cited Publications Cholanoic acid(Standard); Desoxycholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Reference Standards G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite
Deoxycholic acid (Standard) is the analytical standard of Deoxycholic acid. This product is intended for research and analytical applications. Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N0593AR

Deoxycholic acid sodium salt (Standard) Sodium deoxycholate (Standard)	Structural Classification Microorganisms Endogenous metabolite Steroids Source Classification	G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Reference Standards
Deoxycholic acid sodium salt (Standard) is the analytical standard of Deoxycholic acid sodium salt. This product is intended for research and analytical applications. Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-N15317

Phocaecholic acid β-Phocaecholic acid	Animals Ketones, Aldehydes, Acids Source Classification	Drug Metabolite
Phocaecholic acid (β-Phocaecholic acid) is a bile acid found in duck bile. Phocaecholic acid can be excreted into bile and partially decarboxylated to nor-chenodeoxycholic acid in rats. Phocaecholic acid is promising for research of bile acid metabolism and related diseases .

HY-W587978

12β-Hydroxyisocholic acid Lagocholic acid; 3α,7α,12β-Trihydroxy-5β-cholanic acid	Endogenous metabolite Steroids Source Classification	Endogenous Metabolite Drug Isomer
12β-Hydroxyisocholic acid (Lagocholic acid) is a bile acid isomer that can be used in the study of bile acid metabolism .

HY-W740611

Trihydroxycoprostane	Structural Classification Endogenous metabolite Steroids Source Classification	Drug Intermediate
Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders .

HY-N3021R

D-chiro-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0468R

Rebaudioside D (Standard)	Structural Classification other families Terpenoids Diterpenoids Plants Source Classification	Reference Standards Acetyl-CoA Carboxylase FXR
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .

HY-B0172BR

Isolithocholic acid (Standard) 3β-Hydroxy-5β-cholanic acid (Standard); 3-Epilithocholic acid (Standard); β-Lithocholic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
Isolithocholic acid (Standard) is the analytical standard of Isolithocholic acid. This product is intended for research and analytical applications. Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate[1][2].

HY-B1907R

Rifamycin sodium (Standard) Rifamycin SV sodium (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic
Rifamycin (sodium) (Standard) is the analytical standard of Rifamycin (sodium). This product is intended for research and analytical applications. Rifamycin sodium (Rifamycin SV sodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation .

HY-N2853R

D-α-Tocopherylquinone (Standard) α-Tocopherylquinone (Standard)	Quinones Microorganisms Benzene Quinones Source Classification	Reference Standards Reactive Oxygen Species (ROS)
D-α-Tocopherylquinone (α-Tocopherylquinone) (Standard) is the analytical standard of D-α-Tocopherylquinone. This product is intended for research and analytical applications. D-α-Tocopherylquinone is a quinone, can be isolated from Phaeodactylum tricornutum. D-α-Tocopherylquinone is an oxidation product of α-Tocopherol (vitamin E). D-α-Tocopherylquinone can act as an anticoagulant and as an antioxidant. D-α-Tocopherylquinone reduces cellular oxidative damage produced by oxidized lipids. D-α-Tocopherylquinone binds to a liver cytosolic protein with a molecular mass of about 40 kDa. D-α-Tocopherylquinone binds to glurathione-S-transferase (GST) and can be transported to the site of metabolism or excreted in the bile .

HY-N13266

5β-Cholestane-3α,7α,12α,25,27-pentol	Structural Classification Natural Products Animals Steroids Source Classification	Endogenous Metabolite
5β-Cholestane-3α,7α,12α,25,27-pentol is a bile alcohol found in amphibian bile. 5β-Cholestane-3α,7α,12α,25,27-pentol serves as a principal or sole constituent of sulfate-conjugated bile salts in gallbladder bile of the caecilian Dermophis mexicanus. 5β-Cholestane-3α,7α,12α,25,27-pentol appears as a minor constituent in bile of the toad Bufo b. formosus. 5β-Cholestane-3α,7α,12α,25,27-pentol may represent the end product of cholesterol metabolism in the caecilian, as bile acids remain undetected in this organism .

Cat. No.	Product Name	Chemical Structure

HY-76847S

Chenodeoxycholic Acid-d4 1 Publications Verification
Chenodeoxycholic Acid-d₄ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-113478S

Ursodeoxycholic acid-d4

Ursodeoxycholic acid-2,2,4,4-d₄ is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection .

HY-76847S3

Chenodeoxycholic acid-d5
Chenodeoxycholic acid-d₅ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S2

Chenodeoxycholic acid-13C
Chenodeoxycholic acid- ¹³C is the ¹³C-labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-76847S1

Chenodeoxycholic Acid-d9
Chenodeoxycholic Acid-d₉ is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-13771S1

Ursodeoxycholic acid-13C

Ursodeoxycholic acid- ¹³C is the ¹³C labeled Ursodeoxycholic acid. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .

HY-133890AS

Tauro-α-muricholic acid-d4 sodium

Tauro-α-muricholic acid-d₄ (sodium) is the deuterium labeled Tauro-α-muricholic acid sodium (HY-133890A). Tauro-α-muricholic acid sodium (T-α-MCA sodium) is a Taurine (HY-B0351)-conjugated primary Bile acid. Tauro-α-muricholic acid sodium is a FXR antagonist with an IC₅₀ of 28 µM. Tauro-α-muricholic acid sodium attenuates other bile acid-activated FXR signaling. Tauro-α-muricholic acid sodium can be used in the research of Alzheimer's disease, glucose metabolism, and lipid metabolism .

HY-76847S4

Chenodeoxycholic acid-d2
Chenodeoxycholic acid-d₂ (CDCA-d₂) is deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

HY-W712932

Chenodeoxycholic Acid-d7
Chenodeoxycholic Acid-d₇ (CDCA-d₇) is the deuterium labeled Chenodeoxycholic Acid (HY-76847). Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

Cat. No.	Product Name		Classification

HY-N0593A

Deoxycholic acid sodium salt 25+ Cited Publications Sodium deoxycholate		Emulsifiers
Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5 .

HY-B0172B

Isolithocholic acid 3β-Hydroxy-5β-cholanic acid; 3-Epilithocholic acid; β-Lithocholic acid		Cholesterol
Isolithocholic acid (β-Lithocholic acid) is an isomer of Lithocholic acid. Isolithocholic acid, a bile acid, is formed by microbial metabolism of Lithocholic acid or Lithocholic acid 3α-sulfate .

HY-133971

Cholesterol 5α,6α-epoxide 5α,6α-Epoxycholesterol		Cholesterol
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.

HY-174687

Human FGFR4 mRNA		mRNA
Human FGFR4 mRNA encodes the human fibroblast growth factor receptor 4 (FGFR4) protein, a tyrosine kinase and cell surface receptor for fibroblast growth factors. FGFR4 is involved in the regulation of several pathways, including cell proliferation, cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis, vitamin D metabolism, glucose uptake, and phosphate homeostasis.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

bile acid metabolism

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products